Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3936972 | 0.85 | REN (0.47) | HPGDLMNAALDH1A1MMP8 | |
| SCHEMBL4040963 | 0.85 | REN (0.47) | HPGDLMNAALDH1A1MMP8 | |
| SCHEMBL4043492 | 0.84 | VNN1 (0.39) | ACEMMP8 | |
| SCHEMBL4044987 | 0.83 | MMP8 (0.51) | ALDH1A1MMP8 | |
| SCHEMBL4041195 | 0.81 | MMP1 (0.41) | ACEMMP8 | |
| SCHEMBL4066973 | 0.81 | HPGD (0.35) | HPGDKDM4ELMNAMAPK1ALDH1A1 | |
| SCHEMBL4039656 | 0.78 | HDAC1 (0.42) | LMNAALDH1A1HTT | |
| SCHEMBL4071248 | 0.76 | CYP3A4 (0.50) | KDM4ECYP3A4ACEMMP8 | |
| SCHEMBL7589895 | 0.76 | LAP3 (0.49) | LMNASMN1; SMN2MMP8 | |
| SCHEMBL4342649 | 0.76 | SMN1; SMN2 (0.52) | HPGDKDM4ELMNAALOX15ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7001911-B2 | Fused cyclic modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-21 | — | — | US | claimed |
| US-20040077606-A1 | Fused cyclic modulators of nuclear hormone receptor function | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-04-22 | — | — | US | claimed |
| US-20030114420-A1 | Fused cyclic modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2003-06-19 | — | — | US | claimed |
| EP-1463728-B1 | FUSED CYCLIC MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2009-01-14 | — | — | EP | disclosed |
| US-7001911-B2 | Fused cyclic modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114420-A1 | Fused cyclic modulators of nuclear hormone receptor function | NCOA1, ESRRA, NR3C1 | HPGD 452/4885KDM4E 2439/4885LMNA 3936/4885 |
| US-20040077606-A1 | Fused cyclic modulators of nuclear hormone receptor function | NCOA1, ESRRA, NR3C1 | HPGD 452/4885KDM4E 2439/4885LMNA 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.